Oculus Innovative Sciences, Inc. (OCLS) Announces Latin American Regulatory Approvals for Microcyn-Based Antiseptic Products

Global healthcare company Oculus Innovative Sciences recently announced new regulatory approvals in Panama and El Salvador for its Microcyn-based antiseptic products under the brand name Microdacyn.

The growth of the company’s Microcyn-based product portfolio, along with its international footprint, has happened synergistically. As Oculus works closely with strong global partners, including its Latin-American partner More Pharma, the company has been continuously announcing new regulatory approvals, new products, and new territories to serve. Ultimately, the availability of Oculus’ Microcyn technology will benefit an expanded global population.

More Pharma plans to begin commercialization of Oculus’ new antiseptic products in Panama and El Salvador during summer 2013. Since More Pharma acquired the license to the Microcyn-based products in August 2012, the company’s customers have come to recognize the Microdacyn brand as a particularly effective product for both advanced wound care and dermatology. This has allowed More Pharma to build on Oculus’ established success in Mexico while further expanding these products into other South and Central American countries as well as the Caribbean.

Oculus is a worldwide healthcare company engaged in designing, manufacturing, and marketing prescription and nonprescription products in more than 20 countries. Addressing unmet medical needs, the company’s products are used for treating patients in surgical/advanced wound management, dermatology, women’s health, and animal health; Oculus is also raising the standard of patient care and lowering overall health costs. Headquartered in Petaluma, Calif., Oculus has manufacturing operations in the U.S. and Latin America.

For more information, visit www.oculusis.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html